Medical device technology to improve sample diagnostic performance without changing workflow

The company develops flow biopsies, a medical device technology thatprovides samples with highly enriched levels of target biomarkers to greatly improve diagnostic performance. Flow biopsies are valuable when the rarity of biomarkers, such as ctDNA/CTCs/circulating bacteria, constrain diagnostic. The flow biopsy device is an intravenous wire that collects the target biomarker from within the bloodstream over time with a specialized shape and coating and providing the enriched material in a small and purified sample for downstream diagnostic tests. The company has just demonstrated in vivo safety and proof-of-concept. The company has developed an intravenous wire that collects cancer cells as they pass through the bloodstream. The process is simple, painless, works with existing catheters and takes just a few hours. Flow biopsies provide reliable cancer samples, safe and painless, making frequent and accurate diagnoses a reality. The flow biopsies provide a better sample.

The 4 cornorstones of the product are: 

• Micro designs surface profile 
• Molecularly engineered coating 
• Catheter compatibility 
• Diagnostic compatibility

Flow biopsies will provide a safer and more reliable alternative to tissue and fluid biopsies that can be performed as often as the physician requires. We improve Dx performance

• Enriched samples: 
• Pre-purified samples
• Closed loop sampling
• Small volume samples
• Simple and safe procedures

We integrate into DX workflow and into the clinical workflow. We provice a scalabele solution and own the IP. We’re in an uncrowded niche. Only two competing technologies are being developed by two other initiatives. We’ll be the next standard in sampling blood.

The company plan is simple:

• Achieve in vivo POC and safety
• Build collaborations with diagnostic incumbents on their specific biomarkers
• Achieve FDA-approval for the most promising product(s) and generate returns
• Generalize the development pipeline. The company collaborate on the road to the clinic. Build collaborations with diagnostic incumbents on their specific biomarkers. The company can collaorate across the board, is improving theire governance and knows the regulatory landscape. The company meet the clinical standard and is already started to implement the quality systems needed and building the expertise.  

Flow biopsies will provide a safer and more reliable alternative to tissue and fluid biopsies that can be performed as often as the physician requires. We’re raising €900K for  step 2a of the plan: setting up collaborations with diagnostic companies  and to prepare step 2b:  finalizing development for first-in-man. We will continuously pursue additional non-dilutive funding, and currently have an ongoing Eurostars application for €500K and IHI consortium application.